Skip to main content

Accelerating Medicines Partnership Alzheimer’s Disease (AMP AD 2.0)

The Accelerating Medicines Partnership Alzheimer's Disease (AMP AD) is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease. The goal of the second iteration of this transformative partnership is to expand the open-science, precompetitive enterprise and enable a true precision medicine approach to target and biomarker discovery.

This will be achieved by leveraging the investment by the National Institute on Aging in a series of foundational grants in the following strategic directions:

  • Expand the molecular profiling in brain, CSF, and blood samples from diverse cohorts
  • Generate longitudinal immunologic profiling data to enable dynamic modeling of the disease trajectory
  • Expand the existing single-cell/single nucleus molecular profiling efforts to build predictive models of the disease at single cell resolution

The foundational grants support the AMP AD Data Coordinating Center at Sage Bionetworks and six multi-institutional and highly cross-disciplinary research teams.

AMP AD 2.0 Foundational Grants

AMP AD Data Coordination Center (U24AG061340)
Principal Investigator:
Lara M. Mangravite, Sage Bionetworks

A Systems Approach to Targeting Innate Immunity in Alzheimer’s Disease (U01AG046139)
Contact Principal Investigator:
Nilufer Ertekin-Taner, Mayo Clinic

Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer’s Disease (U01AG046170)
Contact Principal Investigator:
Bin Zhang, Icahn School of Medicine at Mount Sinai

Multi-omic Network-Directed Proteoform Discovery, Dissection and Functional Validation to Prioritize Novel Alzheimer’s Disease Therapeutic Targets (U01AG061356)
Contact Principal Investigator:
Philip L. De Jager, Columbia University Health Sciences

AMP AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers (U01AG061357)
Contact Principal Investigator:
Allan I. Levey, Emory University

Metabolomic Signatures for Disease Sub-Classification and Target Prioritization in AMP AD (U01AG061359)
Contact Principal Investigator:
Rima F. Kaddurah-Daouk, Duke University

Identification of the Genetic and Transcriptomic Networks of Cognitive and Neuropathological Resilience to Alzheimer’s Disease Associated Viruses (U01AG061835)
Principal Investigator:
Benjamin Readhead, Arizona State University

Funding

Total project funding ($M) Total NIH funding ($M) Total partner funding ($M)
$74.9 $61.4 $13.5

AMP AD 2.0 Partners

Government

Industry

Nonprofit and Other Private Organizations

AMP AD 2.0 Governance

AMP is a multi-sector partnership managed by the FNIH. NIH and industry partners share expertise and resources in an integrated governance structure that enables the best-informed contributions to science from all participants.

The AMP AD Steering Committee convenes monthly to discuss project plans and review ongoing progress and milestones. The AMP AD Steering Committee is managed by the FNIH, and it consists of representatives from NIA, NINDS, FDA, and private partner organizations. NIA program staff members provide scientific and administrative direction and oversee the cooperative grants that constitute the foundation for the AMP AD 2.0 program.

View Other AMP AD Pages